Business News Technology

Over $5 Billion in Medical Technology Financing in 2011

PatrickDriscoll

2 Min Read

Financings in medical technology reached $451 million in December, bringing the total financings in medtech to over $5.2 billion for 2011. This is more than a 42% increase over the total for 2010, reflecting growing confidence in the future prospects for medtech:

Financings in medical technology reached $451 million in December, bringing the total financings in medtech to over $5.2 billion for 2011. This is more than a 42% increase over the total for 2010, reflecting growing confidence in the future prospects for medtech:

Source: MedMarket Diligence, LLC

Noteworthy financings during the month of December include the following:

HeartFlow, Inc. ($65M) — cardiovascular diagnostics based on computed tomography measurement of functional flow reserve
AcuFocus, Inc. ($42M) — corneal inlay implant for vision correction
Tissue Regenix Group plc ($39M) – tissue decellularization to reduce immunogenicity of tissue transplants
Uptake Medical Corp. ($35M) — endoscopic lung volume reduction
Ember Therapeutics ($34M) – treatments of metabolic orders (e.g., diabetes) and obesity
Hansen Medical, Inc. ($30M) — catheter robotics technologies

The complete list of medtech financings for the month of December 2011 is shown at link.

For the month-by-month totals of medtech financing in 2010 and 2011, with links to lists of companies financed, see our prior post.

TAGGED:MedTech financing

Share This Article

By PatrickDriscoll

Follow:

I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses.Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.